BA
CELG

BKS Advisors’s Celgene Corp CELG Stock Holding History

BKS Advisors’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-35,918
Closed -$3.88M – 169
2015
Q3 		$3.88M Sell
35,918
-32,158
-47% -$3.99M 2.16% 14
2015
Q2 		$7.88M Sell
68,076
-1,760
-3% -$201K 3.76% 1
2015
Q1 		$8.05M Buy
+69,836
New +$8.34M 3.83% 2

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

BKS Advisors's CELG Position: Q4 2015 in Review

BKS Advisors sold out of Celgene Corp (CELG) in Q4 2015, closing a stake of 35,918 shares — an estimated $3.88M sold.

BKS Advisors first reported a position in CELG in Q1 2015 and held it in 3 quarters. The position peaked at $8.05M in Q1 2015. 1,246 funds tracked by Wall St. Rank hold CELG as of Q4 2015.

  • BKS Advisors reported no remaining Celgene Corp position as of Q4 2015 after selling out during the quarter.
  • BKS Advisors sold 35,918 Celgene Corp shares in Q4 2015, an estimated $3.88M.
  • BKS Advisors first reported a position in Celgene Corp in Q1 2015 and held it in 3 quarters.
  • BKS Advisors's Celgene Corp position peaked at $8.05M in Q1 2015.
  • 1,246 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2015.

Based on BKS Advisors's 13F filing for Q4 2015, filed 2 Feb 2016.